DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma

Information source: National Cancer Institute (NCI)
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Precancerous Condition

Intervention: sulindac (Drug); placebo (Other); laboratory biomarker analysis (Other)

Phase: Phase 2

Status: Completed

Sponsored by: National Cancer Institute (NCI)

Official(s) and/or principal investigator(s):
Hsiao-Hui (Sherry) Chow, Principal Investigator, Affiliation: University of Arizona Health Sciences Center


This randomized phase II trial is studying how well sulindac works in preventing melanoma in healthy participants who are at increased risk of melanoma. Sulindac may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether sulindac is more effective than a placebo in preventing melanoma in individuals with many moles and abnormal moles.

Clinical Details

Official title: Phase II Trial of Sulindac in Individuals at Increased Risk for Melanoma

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

Primary outcome:

Sulindac Concentration in the Nevi (Moles)

Sulindac Sulfone, an Active Metabolite of Sulindac, Concentration in the Nevi

Sulindac Sulfide, an Active Metabolite of Sulindac, Concentration in the Nevi

Secondary outcome:

Sulindac Effects on Apoptosis in Atypical Nevi

Sulindac Effects on Vascular Endothelial Growth Factor (VEGF) Expression in Atypical Nevi

Association Between Plasma and Target Tissue Drug Levels

Detailed description: PRIMARY OBJECTIVE: I. To determine sulindac and metabolite levels in healthy participants with atypical nevi and benign nevus at increased risk for melanoma treated with sulindac versus placebo. SECONDARY OBJECTIVES: I. To assess the effects of sulindac on apoptosis in atypical nevi of these participants. II. To assess the effects of sulindac on VEGF expression in atypical nevi of these participants. III. To assess sulindac and metabolite levels in plasma and its association with drug levels in the target tissue. OUTLINE: This is a multicenter study. Participants are randomized to 1 of 2 treatment arms. ARM I: Participants receive oral sulindac twice daily. ARM II: Participants receive oral placebo twice daily. In both arms, treatment continues for 8 weeks in the absence of unacceptable toxicity. Blood and tissue samples are collected at baseline and/or after completion of study therapy and analyzed for sulindac and metabolite levels via high performance liquid chromatography tandem mass spectrometry; the detection of apoptotic cells via TUNEL assay; and VEGF expression via immunohistochemistry assays. After completion of study therapy, participants are followed for 2 weeks.


Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.



- Healthy participants at risk for developing melanoma and meeting the following

criteria: must have >= 4 large (>= 5 mm and < 15 mm) atypical nevi and have 1 benign nevus amenable to biopsies

- No histologically confirmed melanoma on the baseline biopsy

- No more than 1 prior cutaneous melanoma

- One prior stage I, IIA, or IIB melanoma allowed provided patients have been off

treatment > 3 months

- Modified dermoscopy score < 4. 8

- Karnofsky performance status 80-100%

- ANC >= 1,500/mm^3

- No family history of melanoma involving >= 2 first degree relatives

- Platelets count >= 100,000/mm^3

- Total bilirubin =< 2. 0 mg/dL

- AST/ALT =< 2. 0 times upper limit of normal

- Creatinine =< 1. 5 mg/dL

- Not pregnant or nursing

- Fertile patients must use effective contraception

- More than 6 months since prior and no concurrent tanning bed use or other methods to

promote sun-tanning

- Willing to minimize sunlight exposure by applying sunscreen/sunblock or wearing

clothing to shield skin during outdoor activity during study participation

- Willing or able to limit alcohol consumption to less than 3 servings a week during

the study period

- No frequent, chronic or moderate/severe gastrointestinal (GI) complaints

- Upper GI problems requiring prescription or nonprescription medical remedies for

symptoms of heartburn, dyspepsia, nausea, or abdominal pain > once a week on average

- History of peptic ulcer, occult or gross intestinal bleeding

- No prior allergic reaction to aspirin (unless subsequent dosing with other NSAIDs has

been well tolerated)

- No history of allergic reaction to lidocaine or xylocaine

- No history of allergic reaction (e. g., urticaria, asthma, or rhinitis) or gastric

intolerance attributed to compounds of similar chemical or biological composition to sulindac

- No invasive cancer or cancer treatment within the past 5 years, except nonmelanoma

skin cancer

- No immunosuppression by medication or disease, including any of the following: AIDS,

oral prednisone, immunosuppressant/immunomodulator (i. e., cyclosporine, chemotherapeutic agent, or biologic therapy)

- No uncontrolled intercurrent illness

- No ongoing or active infection

- No symptomatic congestive heart failure

- No unstable angina pectoris

- No cardiac arrhythmia

- No psychiatric illness/social situations that would limit compliance with study


- At least 30 days since prior participation and no concurrent enrollment or planning

to enroll in another clinical trial

- No NSAIDs for more than 5 days per month within the past 3 months and no concurrent

non-study NSAIDs, except low dose aspirin (81 mg/day)

- Willing or able to refrain from herbal medicines, above-standard vitamins, or

minerals during study

- Standard daily multivitamin/mineral supplement (i. e., therapeutic doses of calcium

and vitamin D for osteoporosis) allowed

- No concurrent lithium, phenytoin, or sulfonamides

- WBC >= 3,000/mm^3

- No history of bleeding or clotting disorder

- At least 3 months since prior and no concurrent coumadin or other systemic

anticoagulant other than aspirin

Locations and Contacts

University of Arizona Health Sciences Center, Tucson, Arizona 85724, United States

Stanford University Hospitals and Clinics, Stanford, California 94305, United States

Additional Information

Starting date: February 2009
Last updated: May 29, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017